-
Published 4/28/2026
Shastry A, Hiller BE, Sanders NL, Tseng AE, Kothari J, O'connell AK, Gertje HP, Ha CT, Murzin E, Traber KE, Lederer JA, Jones MR, Douam F, Beach TG, Remick DG, Crossland NA, Monti S, Campbell JD, Mizgerd JP. Sub-phenotypes of pneumonia defined by pulmonary histopathological features. Am J Respir Crit Care Med. 2026 Apr 28. PMID: 42089675.
-
Published 4/14/2026
Streicher F, Kenney D, Caval V, Chazal M, Aicher S-M, Gracias S, Adams S, Matsuo M, Roesch F, Douam F, Jouvenet N. Type I and III interferon responses restrict infection by tick-borne orthoflaviviruses through IFI6. J Virol. 2026 May 19; 100(5):e0076025. PMID: 41979927.
-
Published 1/5/2026
Subramaniam S, Napoleon MA, Lotfollahzadeh S, Kamal MH, Kurniawan H, Francis C, Elsadawi M, Wu Wong DJ, Kenney D, Douam F, Bosmann M, Whelan SA, Cabral H, Burks EJ, Zhao G, Kolachalama VB, Ravid K, Chitalia VC. Tryptophan metabolism reprogramming potentially contributes to the prothrombotic milieu in mice and humans with SARS-CoV-2. Blood Vessel Thromb Hemost. 2026 Feb; 3(1):100128. PMID: 41743170.
-
Published 9/29/2025
Unali G, Douam F. Orthoflavivirus Vaccine Platforms: Current Strategies and Challenges. Vaccines (Basel). 2025 Sep 29; 13(10). PMID: 41150403.
-
Published 9/8/2025
Kenney D, O'Connell AK, Tseng AE, Turcinovic J, Sheehan ML, Nitido AD, Montanaro P, Gertje HP, Ericsson M, Connor JH, Vrbanac V, Crossland NA, Harly C, Balazs AB, Douam F. Immune signatures of SARS-CoV-2 infection resolution in human lung tissues. PLoS Pathog. 2025 Sep; 21(9):e1013469. PMID: 40920821.